Substance
ID:805
Names and Identifiers
Brand Name
SigafamSupertidineTaminUlcofamUlfagelUlfamPepcidin RapitabPepcidinePepdinePeptanQuamtelRubacinaMosulNeocidineNovo-FamotidineNu-FamotidineNulcerinPepcid ACFamodineFamovaneFanobelGanorGasterHacipDipsinDuovelDuraterEvatinFadineFadynApo-FamotidineBrolinCepalCronolCuantinDinulRestadinUlcatifUlfinolYamarinPepcid RPDPepcidinaPepdulPeptidinPeptifamRenapepsaTopcidUlfamidVagostalPanalbaMotiaxMucloxMylanta ARPurifamQuamatelTairalTipodexUlcepraxUlgarineWeimokWhitidinPepcidinPepdifPepfaminPepzanRogastiSedanium-RInviganMensomaNevofamNotidinNulceranPepcidFarmotexGastridanGastroGastrodominaGastrosidinIngastriFamodinFamogardFamonitFamosanFamtacFanosinAntodineDibrit 40DigervinFagastineFamoFamocidFibonelGastridinGastropenLogosMidefamAmfamoxFamodarFamotinFamowalFamoxalFamulcerFerotineHuberdinaLecedilBestidineBlocacidDispromilDispronilFanoxFluxidFudoneGastrionGastrofamH2 BlocFamodilFamopsinFamosFamotalFamotepFamoxApogastineConfobosFadin
Synonyms
Famotidinum [Latin]FamotidineFamotidina [Spanish]
IUPAC Traditional name
famotidine
IUPAC name
3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide
Properties
Physical Property
Hydrophobicity(logP)
-2.1
Solubility
1.1 mg/mL
Molecule Details
Drug Groups
approved
Description
A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. [PubChem]
Indication
For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).
Pharmacology
Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms.
Toxicity
Intravenous, mouse: LD50 = 244.4mg/kg; Oral, mouse: LD50 = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse.
Affected Organisms
Humans and other mammals
Biotransformation
Hepatic.
Absorption
The bioavailability of oral doses is 40-45%.
Half Life
2.5-3.5 hours
Protein Binding
15-20%
Elimination
Renal clearance is 250-450 mL/min, indicating some tubular excretion.
Clearance
* renal cl=250-450 mL/min
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data